Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04423549

Enrollment

800

Registered

2020-06-09

Start date

2020-06-30

Completion date

2021-06-30

Last updated

2020-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B Cell Lymphoma

Brief summary

The purpose of this study is to determine the predictive value of a mRNA signature and liquid biopsy in patients with Diffuse Large B cell lymphoma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* biopsy proved Diffuse Large B cell Lymphoma * newly diagnosed between 2000-01 and 2015-12

Exclusion criteria

* patients with biopsy samples unavailable

Design outcomes

Primary

Measure	Time frame
Overall survival	5-years

Countries

China

Contacts

Primary ContactQing qing Cai, MD

caiqq@sysucc.org.cn0086-20-87342823

Outcome results